Europe provides €172m for research into innovative medicinesBMJ 2011; 342 doi: http://dx.doi.org/10.1136/bmj.d1577 (Published 10 March 2011) Cite this as: BMJ 2011;342:d1577
- Rory Watson
The second wave of medical research projects funded by the European Union’s largest biopharmaceutical public-private partnership was announced in Brussels on 8 March. The eight programmes aim to develop new treatments for cancer, rheumatoid arthritis, and infectious diseases.
The €172m (£147m; $238m) cost of the projects is being provided by the EU’s Innovative Medicines Initiative (www.imi.europa.eu/), a partnership between the European Commission and the European Federation of Pharmaceutical Industries and Associations.
Commenting on the latest funding, Máire Geoghegan-Quinn, the European …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial